A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

Blood - Tập 118 - Trang 1255-1263 - 2011
Xiuli Wang1, Wen-Chung Chang1, ChingLam W. Wong1, David Colcher1, Mark Sherman1, Julie R. Ostberg1, Stephen J. Forman1, Stanley R. Riddell2, Michael C. Jensen2,3
1Departments of Cancer Immunotherapeutics & Tumor Immunology, and Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA;
2Program in Immunology, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA; and
3Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA

Tóm tắt

AbstractAn unmet need in cell engineering is the availability of a single transgene encoded, functionally inert, human polypeptide that can serve multiple purposes, including ex vivo cell selection, in vivo cell tracking, and as a target for in vivo cell ablation. Here we describe a truncated human EGFR polypeptide (huEGFRt) that is devoid of extracellular N-terminal ligand binding domains and intracellular receptor tyrosine kinase activity but retains the native amino acid sequence, type I transmembrane cell surface localization, and a conformationally intact binding epitope for pharmaceutical-grade anti-EGFR monoclonal antibody, cetuximab (Erbitux). After lentiviral transduction of human T cells with vectors that coordinately express tumor-specific chimeric antigen receptors and huEGFRt, we show that huEGFRt serves as a highly efficient selection epitope for chimeric antigen receptor+ T cells using biotinylated cetuximab in conjunction with current good manufacturing practices (cGMP)-grade anti-biotin immunomagnetic microbeads. Moreover, huEGFRt provides a cell surface marker for in vivo tracking of adoptively transferred T cells using both flow cytometry and immunohistochemistry, and a target for cetuximab-mediated antibody-dependent cellular cytotoxicity and in vivo elimination. The versatility of huEGFRt and the availability of pharmaceutical-grade reagents for its clinical application denote huEGFRt as a significant new tool for cellular engineering.

Tài liệu tham khảo

Cooper, 2005, T-cell genetic modification for re-directed tumor recognition., Cancer Chemother Biol Response Modif, 22, 293, 10.1016/S0921-4410(04)22014-2 Berger, 2006, Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation., Blood, 107, 2294, 10.1182/blood-2005-08-3503 Jensen, 2010, Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans., Biol Blood Marrow Transplant, 16, 1245, 10.1016/j.bbmt.2010.03.014 Fehse, 2000, CD34 splice variant: an attractive marker for selection of gene-modified cells., Mol Ther, 1, 448, 10.1006/mthe.2000.0068 Fecci, 2007, Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function., Clin Cancer Res, 13, 2158, 10.1158/1078-0432.CCR-06-2070 Tey, 2007, Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation., Biol Blood Marrow Transplant, 13, 913, 10.1016/j.bbmt.2007.04.005 Gaines, 1999, pIRES-CD4t, a dicistronic expression vector for MACS- or FACS-based selection of transfected cells., Biotechniques, 26, 683, 10.2144/99264st04 Lemoine, 2004, Efficient transduction and selection of human T-lymphocytes with bicistronic Thy1/HSV1-TK retroviral vector produced by a human packaging cell line., J Gene Med, 6, 374, 10.1002/jgm.538 Ferguson, 2008, Structure-based view of epidermal growth factor receptor regulation., Annu Rev Biophys, 37, 353, 10.1146/annurev.biophys.37.032807.125829 Li, 2005, Structural basis for inhibition of the epidermal growth factor receptor by cetuximab., Cancer Cell, 7, 301, 10.1016/j.ccr.2005.03.003 Kowolik, 2006, CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells., Cancer Res, 66, 10995, 10.1158/0008-5472.CAN-06-0160 Szymczak, 2004, Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector., Nat Biotechnol, 22, 589, 10.1038/nbt957 Yam, 2002, Design of HIV vectors for efficient gene delivery into human hematopoietic cells., Mol Ther, 5, 479, 10.1006/mthe.2002.0558 Numbenjapon, 2007, Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells., Exp Hematol, 35, 1083, 10.1016/j.exphem.2007.04.007 Pelloquin, 1986, Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A., In Vitro Cell Dev Biol, 22, 689, 10.1007/BF02621085 Wang, 2011, Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice., Blood, 117, 1888, 10.1182/blood-2010-10-310599 Stastny, 2007, Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells., J Pediatr Hematol Oncol, 29, 669, 10.1097/MPH.0b013e3181468c68 Kahlon, 2004, Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells., Cancer Res, 64, 9160, 10.1158/0008-5472.CAN-04-0454 Reagan-Shaw, 2008, Dose translation from animal to human studies revisited., FASEB J, 22, 659, 10.1096/fj.07-9574LSF Dawson, 2005, Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface., Mol Cell Biol, 25, 7734, 10.1128/MCB.25.17.7734-7742.2005 Nijmeijer, 2010, A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL., Blood, 116, 5930, 10.1182/blood-2010-01-262006 Zhang, 2003, Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H., Cancer Res, 63, 6453 Piloto, 2005, Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice., Cancer Res, 65, 1514, 10.1158/0008-5472.CAN-04-3081 Shultz, 1995, Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice., J Immunol, 154, 180, 10.4049/jimmunol.154.1.180 Cooper, 2003, T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect., Blood, 101, 1637, 10.1182/blood-2002-07-1989 Yang, 2008, Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition., Gene Ther, 15, 1411, 10.1038/gt.2008.90 Hakenberg, 2003, MAPPP: MHC class I antigenic peptide processing prediction., Appl Bioinformatics, 2, 155 Hartmann, 2010, Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response., Oncogene, 29, 4517, 10.1038/onc.2010.195 Diaz Miqueli, 2007, Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities., Hybridoma (Larchmt), 26, 423, 10.1089/hyb.2007.0516 Hara, 2008, Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity., Cancer Sci, 99, 1471, 10.1111/j.1349-7006.2008.00821.x Kimura, 2007, Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor., Cancer Sci, 98, 1275, 10.1111/j.1349-7006.2007.00510.x Roda, 2007, The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines., Clin Cancer Res, 13, 6419, 10.1158/1078-0432.CCR-07-0865 Griffioen, 2009, Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy., Haematologica, 94, 1316, 10.3324/haematol.2008.001677 Serafini, 2004, Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease., Hum Gene Ther, 15, 63, 10.1089/10430340460732463 van Meerten, 2006, The CD20/alphaCD20 ‘suicide’ system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells., Gene Ther, 13, 789, 10.1038/sj.gt.3302705 Vogler, 2010, An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy., Mol Ther, 18, 1330, 10.1038/mt.2010.83
Thông tin
Thông tin xuất bản

Blood

Tập 118

1255-1263

Thông tin tác giả